Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Historical Event Reporting
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
        • 2020
        • 2021
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • New 5-year Strategic Agreement
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2022
    • News 2021
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / GBMA Code of Practice / Annual Review / 2013

2013

The Generic Medicines Industry Association (GMiA) is pleased to announce the completion of its Code of Practice review for 2013.   The review indicates that the Code has been effective in formalising the high standards of conduct adhered to by its Members.

Pursuant to section 15 of the Code, the Code Administration Committee was convened in October 2013 to ensure the successful implementation and ongoing effectiveness of the Code. The Committee prepared its annual report for the GMiA Board. This report is posted below.

CodePDF

 

 

 

 

GMiA Code of Practice Review Nov 2013

As set out in section 13 of the Code, an Independent Reviewer has reviewed the Educational Event Reports submitted by Members and conducted spot audits of Members’ marketing and promotional material to determine compliance with the Code.  The Independent Reviewer concluded that there was nothing to indicate any level of non-compliance by Members. The Independent Reviewer’s report is posted below.

imagesCANP5FVD

 

Final Independent Review Report 2013

Our Members

logo_ACCORD
logo_ACCORD
Organon logo
Organon logo
Juno
Juno
Sandoz logo
Sandoz logo
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
commercial_eyes
commercial_eyes
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

Health Minister, Greg Hunt MP and Shadow Health Minister, Mark Butler MP both applaud the role of the GBMA Strategic Agreement for the security of the supply of vital medicines

April 1, 2022

Friday March 1, 2022 Canberra, ACT In one of his last speeches in Parliament as the … More...

Health Minister, Greg Hunt MP and Shadow Minister, Mark Butler MP confirmed as VIP speakers at the GBMA Industry Budget Week luncheon

March 15, 2022

Embargoed until Tuesday March 15, 2022 Canberra, … More...

Australia’s peak body for affordable medicines welcomes a new board member

February 15, 2022

Embargoed until Tuesday February 15, 2022 Canberra, … More…

© 2022 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us